Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery.

European thyroid journal

Elbers LP, Boon HA, Moes MI, van Zaane B, Brandjes DP, Fliers E, Büller HR, Cannegieter S, Gerdes VE.
PMID: 27493889
Eur Thyroid J. 2016 Jul;5(2):139-44. doi: 10.1159/000446431. Epub 2016 Jun 14.

BACKGROUND: In a recent study of patients using vitamin K antagonists, those with low free thyroxin (FT4) levels within the normal range had a 3- to 5-fold increased risk of major bleeding. We tested the hypothesis that low levels...

Cite
Elbers LP, Boon HA, Moes MI, et al. Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery. Eur Thyroid J. 2016;5(2):139-44doi: 10.1159/000446431.
Elbers, L. P., Boon, H. A., Moes, M. I., van Zaane, B., Brandjes, D. P., Fliers, E., Büller, H. R., Cannegieter, S., & Gerdes, V. E. (2016). Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery. European thyroid journal, 5(2), 139-44. https://doi.org/10.1159/000446431
Elbers, Laura P B, et al. "Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery." European thyroid journal vol. 5,2 (2016): 139-44. doi: https://doi.org/10.1159/000446431
Elbers LP, Boon HA, Moes MI, van Zaane B, Brandjes DP, Fliers E, Büller HR, Cannegieter S, Gerdes VE. Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery. Eur Thyroid J. 2016 Jul;5(2):139-44. doi: 10.1159/000446431. Epub 2016 Jun 14. PMID: 27493889; PMCID: PMC4949359.
Copy Download .nbib Format: NLM
Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort.

Clinical epidemiology

Jensvoll H, Severinsen MT, Hammerstrøm J, Brækkan SK, Kristensen SR, Cannegieter SC, Blix K, Tjønneland A, Rosendaal FR, Dziewiecka O, Overvad K, Næss IA, Hansen JB.
PMID: 26396546
Clin Epidemiol. 2015 Sep 16;7:401-10. doi: 10.2147/CLEP.S84279. eCollection 2015.

BACKGROUND: Although venous thromboembolism (VTE) is a known common complication in cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established by merging individual...

Cite
Jensvoll H, Severinsen MT, Hammerstrøm J, et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol. 2015;7:401-10doi: 10.2147/CLEP.S84279.
Jensvoll, H., Severinsen, M. T., Hammerstrøm, J., Brækkan, S. K., Kristensen, S. R., Cannegieter, S. C., Blix, K., Tjønneland, A., Rosendaal, F. R., Dziewiecka, O., Overvad, K., Næss, I. A., & Hansen, J. B. (2015). Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clinical epidemiology, 7401-10. https://doi.org/10.2147/CLEP.S84279
Jensvoll, Hilde, et al. "Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort." Clinical epidemiology vol. 7 (2015): 401-10. doi: https://doi.org/10.2147/CLEP.S84279
Jensvoll H, Severinsen MT, Hammerstrøm J, Brækkan SK, Kristensen SR, Cannegieter SC, Blix K, Tjønneland A, Rosendaal FR, Dziewiecka O, Overvad K, Næss IA, Hansen JB. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol. 2015 Sep 16;7:401-10. doi: 10.2147/CLEP.S84279. eCollection 2015. PMID: 26396546; PMCID: PMC4577261.
Copy Download .nbib Format: NLM
Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study.

Research and practice in thrombosis and haemostasis

Brækkan SK, Caram-Deelder C, Siegerink B, van Hylckama Vlieg A, le Cessie S, Rosendaal FR, Cannegieter SC, Lijfering WM.
PMID: 30046679
Res Pract Thromb Haemost. 2017 May 25;1(1):112-119. doi: 10.1002/rth2.12003. eCollection 2017 Jul.

INTRODUCTION: Whether statin use after first venous thrombosis reduces the risk of recurrence is uncertain. Therefore, we aimed to examine the risk of recurrent venous thrombosis in statin users vs non-users.METHODS: Patients with a first venous thrombosis were recruited...

Cite
Brækkan SK, Caram-Deelder C, Siegerink B, et al. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemost. 2017;1(1):112-119doi: 10.1002/rth2.12003.
Brækkan, S. K., Caram-Deelder, C., Siegerink, B., van Hylckama Vlieg, A., le Cessie, S., Rosendaal, F. R., Cannegieter, S. C., & Lijfering, W. M. (2017). Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Research and practice in thrombosis and haemostasis, 1(1), 112-119. https://doi.org/10.1002/rth2.12003
Brækkan, Sigrid K, et al. "Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study." Research and practice in thrombosis and haemostasis vol. 1,1 (2017): 112-119. doi: https://doi.org/10.1002/rth2.12003
Brækkan SK, Caram-Deelder C, Siegerink B, van Hylckama Vlieg A, le Cessie S, Rosendaal FR, Cannegieter SC, Lijfering WM. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemost. 2017 May 25;1(1):112-119. doi: 10.1002/rth2.12003. eCollection 2017 Jul. PMID: 30046679; PMCID: PMC6058203.
Copy Download .nbib Format: NLM
Cardiovascular risk in young apparently healthy descendents from Asian Indian migrants in the Netherlands: the SHIVA study.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Liem SS, Oemrawsingh PV, Cannegieter SC, Le Cessie S, Schreur J, Rosendaal FR, Schalij MJ.
PMID: 19421361
Neth Heart J. 2009 Apr;17(4):155-61. doi: 10.1007/BF03086238.

BACKGROUND.: Asian Indian migrants in the Western world are highly susceptible for ischaemic heart disease (IHD). Until now, most IHD risk studies were performed in first and second generation Asian Indian expatriates. For optimal prevention, knowledge of the cardiovascular...

Cite
Liem SS, Oemrawsingh PV, Cannegieter SC, et al. Cardiovascular risk in young apparently healthy descendents from Asian Indian migrants in the Netherlands: the SHIVA study. Neth Heart J. 2009;17(4):155-61doi: 10.1007/BF03086238.
Liem, S. S., Oemrawsingh, P. V., Cannegieter, S. C., Le Cessie, S., Schreur, J., Rosendaal, F. R., & Schalij, M. J. (2009). Cardiovascular risk in young apparently healthy descendents from Asian Indian migrants in the Netherlands: the SHIVA study. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 17(4), 155-61. https://doi.org/10.1007/BF03086238
Liem, S S, et al. "Cardiovascular risk in young apparently healthy descendents from Asian Indian migrants in the Netherlands: the SHIVA study." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 17,4 (2009): 155-61. doi: https://doi.org/10.1007/BF03086238
Liem SS, Oemrawsingh PV, Cannegieter SC, Le Cessie S, Schreur J, Rosendaal FR, Schalij MJ. Cardiovascular risk in young apparently healthy descendents from Asian Indian migrants in the Netherlands: the SHIVA study. Neth Heart J. 2009 Apr;17(4):155-61. doi: 10.1007/BF03086238. PMID: 19421361; PMCID: PMC2669245.
Copy Download .nbib Format: NLM
Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort.

TH open : companion journal to thrombosis and haemostasis

Gade IL, Brækkan SK, Næss IA, Hansen JB, Cannegieter SC, Rosendaal FR, Overvad K, Hindberg K, Hammerstrøm J, Gran OV, Tjønneland A, Severinsen MT, Kristensen SR.
PMID: 31249936
TH Open. 2018 Apr 06;2(2):e131-e138. doi: 10.1055/s-0038-1641678. eCollection 2018 Apr.

The risk of venous thromboembolism (VTE) in patients who survive the first years after a cancer diagnosis after the acute effects of disease and treatment in comparison to a similar background population has been sparsely investigated. The aim of...

Cite
Gade IL, Brækkan SK, Næss IA, et al. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open. 2018;2(2):e131-e138doi: 10.1055/s-0038-1641678.
Gade, I. L., Brækkan, S. K., Næss, I. A., Hansen, J. B., Cannegieter, S. C., Rosendaal, F. R., Overvad, K., Hindberg, K., Hammerstrøm, J., Gran, O. V., Tjønneland, A., Severinsen, M. T., & Kristensen, S. R. (2018). Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH open : companion journal to thrombosis and haemostasis, 2(2), e131-e138. https://doi.org/10.1055/s-0038-1641678
Gade, Inger Lise, et al. "Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort." TH open : companion journal to thrombosis and haemostasis vol. 2,2 (2018): e131-e138. doi: https://doi.org/10.1055/s-0038-1641678
Gade IL, Brækkan SK, Næss IA, Hansen JB, Cannegieter SC, Rosendaal FR, Overvad K, Hindberg K, Hammerstrøm J, Gran OV, Tjønneland A, Severinsen MT, Kristensen SR. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open. 2018 Apr 06;2(2):e131-e138. doi: 10.1055/s-0038-1641678. eCollection 2018 Apr. PMID: 31249936; PMCID: PMC6524868.
Copy Download .nbib Format: NLM
Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients.

Research and practice in thrombosis and haemostasis

Stals M, Grootenboers M, van Guldener C, Kaptein F, Braken S, Chen Q, Chu G, van Driel EM, Iglesias Del Sol A, de Jonge E, Kant KM, Pals F, Toorop M, Cannegieter SC, Klok FA, Huisman MV.
PMID: 33821230
Res Pract Thromb Haemost. 2021 Feb 17; doi: 10.1002/rth2.12496. Epub 2021 Feb 17.

BACKGROUND: Whereas accumulating studies on COVID-19 patients report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID-19 patients compares to those observed...

Cite
Stals M, Grootenboers M, van Guldener C, et al. Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. Res Pract Thromb Haemost. 2021;doi: 10.1002/rth2.12496.
Stals, M., Grootenboers, M., van Guldener, C., Kaptein, F., Braken, S., Chen, Q., Chu, G., van Driel, E. M., Iglesias Del Sol, A., de Jonge, E., Kant, K. M., Pals, F., Toorop, M., Cannegieter, S. C., Klok, F. A., Huisman, M. V. (2021). Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. Research and practice in thrombosis and haemostasis, . https://doi.org/10.1002/rth2.12496
Stals, Mam, et al. "Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients." Research and practice in thrombosis and haemostasis vol. (2021). doi: https://doi.org/10.1002/rth2.12496
Stals M, Grootenboers M, van Guldener C, Kaptein F, Braken S, Chen Q, Chu G, van Driel EM, Iglesias Del Sol A, de Jonge E, Kant KM, Pals F, Toorop M, Cannegieter SC, Klok FA, Huisman MV. Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. Res Pract Thromb Haemost. 2021 Feb 17; doi: 10.1002/rth2.12496. Epub 2021 Feb 17. PMID: 33821230; PMCID: PMC8014477.
Copy Download .nbib Format: NLM
High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study.

Thrombosis and haemostasis

Toorop MMA, van Rein N, Cannegieter SC, van der Meer FJM, Reitsma PH, Lijfering WM, Bos MHA.
PMID: 32854121
Thromb Haemost. 2021 Jan;121(1):70-75. doi: 10.1055/s-0040-1715459. Epub 2020 Aug 27.

BACKGROUND:  Major bleeding occurs in 1 to 3% of patients treated with oral anticoagulants per year. Biomarkers may help to identify high-risk patients. A proposed marker for major bleeding while using anticoagulants is soluble thrombomodulin (sTM).METHODS:  Plasma was available...

Cite
Toorop MMA, van Rein N, Cannegieter SC, et al. High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study. Thromb Haemost. 2020;121(1):70-75doi: 10.1055/s-0040-1715459.
Toorop, M. M. A., van Rein, N., Cannegieter, S. C., van der Meer, F. J. M., Reitsma, P. H., Lijfering, W. M., & Bos, M. H. A. (2021). High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study. Thrombosis and haemostasis, 121(1), 70-75. https://doi.org/10.1055/s-0040-1715459
Toorop, Myrthe M A, et al. "High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study." Thrombosis and haemostasis vol. 121,1 (2021): 70-75. doi: https://doi.org/10.1055/s-0040-1715459
Toorop MMA, van Rein N, Cannegieter SC, van der Meer FJM, Reitsma PH, Lijfering WM, Bos MHA. High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study. Thromb Haemost. 2021 Jan;121(1):70-75. doi: 10.1055/s-0040-1715459. Epub 2020 Aug 27. PMID: 32854121.
Copy Download .nbib Format: NLM
Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.

Journal of thrombosis and haemostasis : JTH

Ramberg C, Hindberg K, Biedermann JS, Cannegieter SC, van der Meer FJ, Snir O, Leebeek FWG, Kruip MJHA, Hansen JB, Lijfering WM.
PMID: 34953155
J Thromb Haemost. 2021 Dec 25; doi: 10.1111/jth.15626. Epub 2021 Dec 25.

BACKGROUND: Venous thromboembolism (VTE) is a frequent cardiovascular disease with severe complications, including recurrence and death. There is a great need for alternative prophylactic treatment options as anticoagulation is accompanied by increased bleeding risk. Statins are reported to reduce...

Cite
Ramberg C, Hindberg K, Biedermann JS, et al. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. J Thromb Haemost. 2021;doi: 10.1111/jth.15626.
Ramberg, C., Hindberg, K., Biedermann, J. S., Cannegieter, S. C., van der Meer, F. J., Snir, O., Leebeek, F. W. G., Kruip, M. J. H. A., Hansen, J. B., & Lijfering, W. M. (2021). Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of thrombosis and haemostasis : JTH, . https://doi.org/10.1111/jth.15626
Ramberg, Cathrine, et al. "Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial." Journal of thrombosis and haemostasis : JTH vol. (2021). doi: https://doi.org/10.1111/jth.15626
Ramberg C, Hindberg K, Biedermann JS, Cannegieter SC, van der Meer FJ, Snir O, Leebeek FWG, Kruip MJHA, Hansen JB, Lijfering WM. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. J Thromb Haemost. 2021 Dec 25; doi: 10.1111/jth.15626. Epub 2021 Dec 25. PMID: 34953155.
Copy Download .nbib Format: NLM
Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.

Research and practice in thrombosis and haemostasis

Krishnaswamy S, Ageno W, Arabi Y, Barbui T, Cannegieter S, Carrier M, Cleuren AC, Collins P, Panicot-Dubois L, Freedman JE, Freson K, Hogg P, James AH, Kretz CA, Lavin M, Leebeek FWG, Li W, Maas C, Machlus K, Makris M, Martinelli I, Medved L, Neerman-Arbez M, O'Donnell JS, O'Sullivan J, Rajpurkar M, Schroeder V, Spiegel PC, Stanworth SJ, Green L, Undas A.
PMID: 34296056
Res Pract Thromb Haemost. 2021 Jul 16;5(5):e12532. doi: 10.1002/rth2.12532. eCollection 2021 Jul.

This year's Congress of the International Society of Thrombosis and Haemostasis (ISTH) was hosted virtually from Philadelphia July 17-21, 2021. The conference, now held annually, highlighted cutting-edge advances in basic, population and clinical sciences of relevance to the Society....

Cite
Krishnaswamy S, Ageno W, Arabi Y, et al. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2021;5(5):e12532doi: 10.1002/rth2.12532.
Krishnaswamy, S., Ageno, W., Arabi, Y., Barbui, T., Cannegieter, S., Carrier, M., Cleuren, A. C., Collins, P., Panicot-Dubois, L., Freedman, J. E., Freson, K., Hogg, P., James, A. H., Kretz, C. A., Lavin, M., Leebeek, F. W. G., Li, W., Maas, C., Machlus, K., Makris, M., Martinelli, I., Medved, L., Neerman-Arbez, M., O'Donnell, J. S., O'Sullivan, J., Rajpurkar, M., Schroeder, V., Spiegel, P. C., Stanworth, S. J., Green, L., & Undas, A. (2021). Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Research and practice in thrombosis and haemostasis, 5(5), e12532. https://doi.org/10.1002/rth2.12532
Krishnaswamy, Sriram, et al. "Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress." Research and practice in thrombosis and haemostasis vol. 5,5 (2021): e12532. doi: https://doi.org/10.1002/rth2.12532
Krishnaswamy S, Ageno W, Arabi Y, Barbui T, Cannegieter S, Carrier M, Cleuren AC, Collins P, Panicot-Dubois L, Freedman JE, Freson K, Hogg P, James AH, Kretz CA, Lavin M, Leebeek FWG, Li W, Maas C, Machlus K, Makris M, Martinelli I, Medved L, Neerman-Arbez M, O'Donnell JS, O'Sullivan J, Rajpurkar M, Schroeder V, Spiegel PC, Stanworth SJ, Green L, Undas A. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2021 Jul 16;5(5):e12532. doi: 10.1002/rth2.12532. eCollection 2021 Jul. PMID: 34296056; PMCID: PMC8285574.
Copy Download .nbib Format: NLM
Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma.

EClinicalMedicine

Nemeth B, Douillet D, le Cessie S, Penaloza A, Moumneh T, Roy PM, Cannegieter S.
PMID: 32300734
EClinicalMedicine. 2020 Feb 04;20:100270. doi: 10.1016/j.eclinm.2020.100270. eCollection 2020 Mar.

BACKGROUND: Patients with lower-limb trauma requiring immobilization have an increased risk of venous thromboembolism (VTE). While thromboprophylaxis for all patients seems not effective, targeted thromboprophylaxis in high risk patients may be an appropriate alternative. Therefore, we aimed to develop...

Cite
Nemeth B, Douillet D, le Cessie S, et al. Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma. EClinicalMedicine. 2020;20:100270doi: 10.1016/j.eclinm.2020.100270.
Nemeth, B., Douillet, D., le Cessie, S., Penaloza, A., Moumneh, T., Roy, P. M., & Cannegieter, S. (2020). Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma. EClinicalMedicine, 20100270. https://doi.org/10.1016/j.eclinm.2020.100270
Nemeth, Banne, et al. "Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma." EClinicalMedicine vol. 20 (2020): 100270. doi: https://doi.org/10.1016/j.eclinm.2020.100270
Nemeth B, Douillet D, le Cessie S, Penaloza A, Moumneh T, Roy PM, Cannegieter S. Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma. EClinicalMedicine. 2020 Feb 04;20:100270. doi: 10.1016/j.eclinm.2020.100270. eCollection 2020 Mar. PMID: 32300734; PMCID: PMC7152815.
Copy Download .nbib Format: NLM
Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Eindhoven DC, van Staveren LN, van Erkelens JA, Ikkersheim DE, Cannegieter SC, Umans VAWM, Mosterd A, van Wijngaarden J, Schalij MJ, Borleffs CJW.
PMID: 29119544
Neth Heart J. 2018 Jan;26(1):13-20. doi: 10.1007/s12471-017-1055-3.

INTRODUCTION: Since health insurance is compulsory in the Netherlands, the centrally registered medical claims data might pose a unique opportunity to evaluate quality of (cardiac) care on a national level without additional collection of data. However, validation of these...

Cite
Eindhoven DC, van Staveren LN, van Erkelens JA, et al. Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands. Neth Heart J. 2018;26(1):13-20doi: 10.1007/s12471-017-1055-3.
Eindhoven, D. C., van Staveren, L. N., van Erkelens, J. A., Ikkersheim, D. E., Cannegieter, S. C., Umans, V. A. W. M., Mosterd, A., van Wijngaarden, J., Schalij, M. J., & Borleffs, C. J. W. (2018). Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 26(1), 13-20. https://doi.org/10.1007/s12471-017-1055-3
Eindhoven, D C, et al. "Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 26,1 (2018): 13-20. doi: https://doi.org/10.1007/s12471-017-1055-3
Eindhoven DC, van Staveren LN, van Erkelens JA, Ikkersheim DE, Cannegieter SC, Umans VAWM, Mosterd A, van Wijngaarden J, Schalij MJ, Borleffs CJW. Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands. Neth Heart J. 2018 Jan;26(1):13-20. doi: 10.1007/s12471-017-1055-3. PMID: 29119544; PMCID: PMC5758448.
Copy Download .nbib Format: NLM
Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials.

Research and practice in thrombosis and haemostasis

Scheres LJJ, Lijfering WM, Middeldorp S, Cheung YW, Barco S, Cannegieter SC, Coppens M.
PMID: 30349888
Res Pract Thromb Haemost. 2018 Aug 18;2(4):689-695. doi: 10.1002/rth2.12142. eCollection 2018 Oct.

BACKGROUND: Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain.OBJECTIVE: To assess...

Cite
Scheres LJJ, Lijfering WM, Middeldorp S, et al. Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. Res Pract Thromb Haemost. 2018;2(4):689-695doi: 10.1002/rth2.12142.
Scheres, L. J. J., Lijfering, W. M., Middeldorp, S., Cheung, Y. W., Barco, S., Cannegieter, S. C., & Coppens, M. (2018). Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. Research and practice in thrombosis and haemostasis, 2(4), 689-695. https://doi.org/10.1002/rth2.12142
Scheres, Luuk J J, et al. "Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials." Research and practice in thrombosis and haemostasis vol. 2,4 (2018): 689-695. doi: https://doi.org/10.1002/rth2.12142
Scheres LJJ, Lijfering WM, Middeldorp S, Cheung YW, Barco S, Cannegieter SC, Coppens M. Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. Res Pract Thromb Haemost. 2018 Aug 18;2(4):689-695. doi: 10.1002/rth2.12142. eCollection 2018 Oct. PMID: 30349888; PMCID: PMC6178718.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries